BRCA2 Loss and Breast Cancer Prognosis
Author Information
Author(s): I Bieche, C Nogubs, S Rivoilan, A Khodja, A Latill, R Lidereau
Primary Institution: Centre Rene Huguenin
Hypothesis
Is loss of heterozygosity at BRCA2 a significant prognostic factor in sporadic breast cancer?
Conclusion
Loss of heterozygosity at BRCA2 does not appear to be a major prognostic marker in sporadic breast cancer.
Supporting Evidence
- LOH at BRCA2 was found in 42.4% of informative tumor DNAs.
- No link was found between BRCA2 status and macroscopic tumor size or lymph node status.
- Oestrogen and progesterone receptor negativity were associated with a higher percentage of LOH at BRCA2.
Takeaway
The study looked at breast cancer patients to see if a specific genetic change (BRCA2 loss) could predict how well they would do. It found that this change doesn't really help in predicting outcomes.
Methodology
The study examined 102 primary breast tumors for loss of heterozygosity at BRCA2 and analyzed patient outcomes over a median follow-up of 9 years.
Limitations
The study focused only on sporadic breast cancer and may not apply to hereditary cases.
Participant Demographics
Participants were 102 women with primary unilateral invasive breast carcinoma, aged 34-86 years.
Statistical Information
P-Value
P = 0.34 for metastasis-free survival, P = 0.29 for overall survival
Want to read the original?
Access the complete publication on the publisher's website